EPO and alopecia: The safety and toxicity profile of epothilones has been the main problem for bringing these drugs to market, ixabepilone, KOS-862, and ZK-EPO (sagopilone) exhibit a high incidence of myelosuppression, alopecia, severe peripheral neuropathy, and hypersensitivity reactions [82,83].